TY - JOUR
T1 - Invasive pulmonary aspergillosis in critically Ill apparently immunocompetent patients
AU - Rishi, Abdul
AU - Sethi, Imran
AU - Jesinger, Michael
AU - Beddawi, Yazen
AU - Morehead, Scott
AU - Khosravi, Mehdi
PY - 2016
Y1 - 2016
N2 - Invasive pulmonary aspergillosis (IPA) is increasingly being recognized as an important infection in critically ill patients who do not have the classic risk factors of immunodeficiency. Background pulmonary disease such as chronic obstructive pulmonary disease and the administration of corticosteroids, even in the short term, may be the most important risk factors in this population. The diagnosis of IPA is extremely difficult in critically ill patients because standard guidelines for the diagnosis of IPA had been developed for immunocompromised patients and have not been validated in immunocompetent critically ill patients. A new algorithm for the diagnosis of IPA has been validated in critically ill patients, which may be useful, but is not without limitations. A high index of suspicion is therefore required. The detection of IPA on the basis of serum galactomannan antigen and the β-Dglucan assay is of little value in non-neutropenic critically ill patients. However, the lateral-flow device test may be a useful diagnostic test in critically ill patients for the diagnosis of IPA. Voriconazole remains the first-line treatment of suspected IPA and should be administered even without confirmed histologic diagnosis, which is usually not possible in critically ill patients due to the overall status of such patients.
AB - Invasive pulmonary aspergillosis (IPA) is increasingly being recognized as an important infection in critically ill patients who do not have the classic risk factors of immunodeficiency. Background pulmonary disease such as chronic obstructive pulmonary disease and the administration of corticosteroids, even in the short term, may be the most important risk factors in this population. The diagnosis of IPA is extremely difficult in critically ill patients because standard guidelines for the diagnosis of IPA had been developed for immunocompromised patients and have not been validated in immunocompetent critically ill patients. A new algorithm for the diagnosis of IPA has been validated in critically ill patients, which may be useful, but is not without limitations. A high index of suspicion is therefore required. The detection of IPA on the basis of serum galactomannan antigen and the β-Dglucan assay is of little value in non-neutropenic critically ill patients. However, the lateral-flow device test may be a useful diagnostic test in critically ill patients for the diagnosis of IPA. Voriconazole remains the first-line treatment of suspected IPA and should be administered even without confirmed histologic diagnosis, which is usually not possible in critically ill patients due to the overall status of such patients.
KW - Critical care
KW - Diffuse alveolar hemorrhage
KW - Invasive aspergillosis
UR - http://www.scopus.com/inward/record.url?scp=84978264654&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978264654&partnerID=8YFLogxK
U2 - 10.1097/CPM.0000000000000161
DO - 10.1097/CPM.0000000000000161
M3 - Article
AN - SCOPUS:84978264654
SN - 1068-0640
VL - 23
SP - 184
EP - 187
JO - Clinical Pulmonary Medicine
JF - Clinical Pulmonary Medicine
IS - 4
ER -